Abstract:Objective To explore the influence factors on the prognosis of patients with hepatitis B-related hepatocellular carcinoma (HCC) treated with transcatheter arterial chemoembolization (TACE). Methods A total of 120 patients with hepatitis B-related HCC, who underwent TACE from January 2013 to December 2015, were randomly selected as the study subjects and were followed up until December 2016 to observe one-year survival after treatment. The related prognostic factors of patients were screened and analyzed. Results The univariate analysis showed that antiviral therapy, low aspartate aminotransferase (AST) level (<80 U/L) , low serum bilirubin level (<34.2 μmol/L) , low Child-Pugh classification, no intra-abdominal metastasis, no pleural metastasis, no portal vein metastasis, younger and more times of interventional treatments were the factors influencing the prognosis of patients (P<0.05 or P<0.01).There was a significant difference in survival condition between patients treated with TACE plus antiviral therapy and patients treated with TACE without antiviral therapy in Child-Pugh A patients (P=0.003).Multivariate analysis showed that the frequency of TACE treatment (P=0.000) , antiviral treatment (P=0.000) , bilirubin level (P=0.017) , peritoneal metastasis (P=0.009) , portal vein metastasis (P=0.004) were related to the prognosis of hepatitis B-related HCC patients treated with TACE. Conclusion Higher bilirubin level, intra-abdominal metastasis and portal vein metastasis may be independent risk factors affecting the prognosis of patients with hepatitis B-related HCC treated with TACE, while antiviral therapy and more times of interventional therapies may be the protective factors.